Valo Health
Valo Health uses large collections of patient health records and artificial intelligence to work out which biological targets cause disease, then designs small-molecule drugs against them.
Overview
Valo Health is a drug discovery company that integrates real-world clinical data, causal inference and predictive chemistry. Its stated approach has two pillars: Human Causal Biology, which applies machine learning and statistical genetics across a data asset of about 17 million de-identified patient records to identify targets validated in human tissue, and Closed-Loop Chemistry, which iteratively explores chemical space and refines models after each experimental round. The company lists offices in Lexington, Massachusetts and New York. In 2026 Valo appointed Karin Conde-Knape as Chief Scientific Officer and Chris Anagnostopoulos as Chief Causal AI Officer. The fetched pages do not name specific therapeutic areas or pipeline programmes, so the extent of its oncology work, its funding history and the Opal platform branding could not be confirmed from primary sources.
Notes
top- Oncology focus not confirmed on fetched pages; pipeline page gives no programmes. Stage set to growth from background knowledge of large private rounds, but no round could be sourced. Founding year not sourced.